SCHEMBL23780467

SCHEMBL23780467

Cc1nc(-c2ccc(CNc3ccnc(Cl)n3)cc2)no1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 10/20 0.50
CLK1 P49759 1/20 0.48
POLB P06746 2/20 0.47
MAPT P10636 2/20 0.47
HDAC1 Q13547 3/20 0.46
HDAC8 Q9BY41 3/20 0.46
HDAC6 Q9UBN7 3/20 0.46
ALDH1A1 P00352 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C19 P33261 2/20 0.45
HSD17B10 Q99714 2/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
KDM4E B2RXH2 1/20 0.44
TP53 P04637 1/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MPO P05164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23780424 0.81 HDAC6 (0.49) CLK4CLK1POLBMAPTHDAC1
SCHEMBL30172454 0.81 HDAC6 (0.47) CLK4POLBMAPTHDAC1HDAC8
SCHEMBL23780452 0.81 HDAC6 (0.47) CLK4POLBMAPTHDAC1HDAC8
SCHEMBL23780406 0.81 HDAC6 (0.50) CLK4POLBMAPTHDAC1HDAC8
SCHEMBL23780453 0.80 PTGS2 (0.44) CLK4POLBMAPTHDAC1HDAC8
SCHEMBL30172327 0.80 POLB (0.46) POLBMAPTHDAC1HDAC8HDAC6
SCHEMBL23780416 0.80 POLB (0.46) POLBMAPTHDAC1HDAC8HDAC6
SCHEMBL23780442 0.79 HDAC1 (0.69) CLK4POLBMAPTHDAC1HDAC8
SCHEMBL23780464 0.78 HDAC6 (0.47) CLK4CLK1POLBMAPTHDAC1
SCHEMBL23780463 0.78 CLK4 (0.52) CLK4CLK1POLBHDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187712-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2025-01-07 US claimed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP claimed
US-12187712-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2025-01-07 US disclosed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP disclosed
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187712-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 CLK4 1617/4885CLK1 1983/4885POLB 4203/4885
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 CLK4 1617/4885CLK1 1983/4885POLB 4203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.